Review
doi: 10.1136/ard.2010.135061.
From bone biology to clinical outcome: state of the art and future perspectives
Affiliations
- PMID: 20650876
- DOI: 10.1136/ard.2010.135061
Item in Clipboard
Review
From bone biology to clinical outcome: state of the art and future perspectives
Ann Rheum Dis.
2010 Aug.
Abstract
In the last decade progress has been made in our understanding of bone biology. In particular, the relation between inflammation and bone has become much clearer, leading to bone-targeting therapies in inflammatory rheumatic diseases. The clinical sequelae of the influences of both inflammation and immobility (due to arthritis) on bone for different rheumatic diseases (such as rheumatoid arthritis, systemic lupus erythematosus and spondyloarthritides) have also now captured the attention of clinicians. In the last decade the well-known negative influences of glucocorticoids on bone have become more treatable as a result of new drugs that stimulate osteoblasts and restore the negative bone balance.
Similar articles
-
Still a blind spot for osteoporosis prevention and treatment for rheumatoid arthritis.J Rheumatol. 2004 Apr;31(4):822; author reply 822-3. J Rheumatol. 2004. PMID: 15095736 No abstract available.
-
Epidemiology of osteoporosis in rheumatic diseases.Rheum Dis Clin North Am. 2006 Nov;32(4):631-58. doi: 10.1016/j.rdc.2006.07.002. Rheum Dis Clin North Am. 2006. PMID: 17288969 Review.
-
[Specialties in therapy of osteoporosis in inflammatory joint disease].Z Rheumatol. 2004 Jun;63(3):223-9. doi: 10.1007/s00393-004-0572-9. Z Rheumatol. 2004. PMID: 15224226 Review. German.
-
Rheumatic disorders and glucocorticoid-induced osteoporosis.Front Horm Res. 2002;30:107-20. doi: 10.1159/000061077. Front Horm Res. 2002. PMID: 11892257 Review. No abstract available.
-
Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.Arthritis Rheum. 2002 Dec;46(12):3136-42. doi: 10.1002/art.10613. Arthritis Rheum. 2002. PMID: 12483716
Cited by
-
Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion.Front Immunol. 2023 Sep 19;14:1254139. doi: 10.3389/fimmu.2023.1254139. eCollection 2023. Front Immunol. 2023. PMID: 37809106 Free PMC article.
-
Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years.BMC Rheumatol. 2023 Aug 7;7(1):23. doi: 10.1186/s41927-023-00347-6. BMC Rheumatol. 2023. PMID: 37550762 Free PMC article.
-
Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis.J Rheum Dis. 2023 Jan 1;30(1):3-17. doi: 10.4078/jrd.22.0046. J Rheum Dis. 2023. PMID: 37476528 Free PMC article. Review.
-
A COX-2 Inhibitor Does Not Interfere With the Bone-Protective Effects of Loading in Male Mice With Arthritis.JBMR Plus. 2023 May 8;7(7):e10751. doi: 10.1002/jbm4.10751. eCollection 2023 Jul. JBMR Plus. 2023. PMID: 37457879 Free PMC article.
-
The Effect of Anti-rheumatic Drugs on the Skeleton.Calcif Tissue Int. 2022 Nov;111(5):445-456. doi: 10.1007/s00223-022-01001-y. Epub 2022 Jun 30. Calcif Tissue Int. 2022. PMID: 35771255 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
